Research in cancer therapeutics has achieved major progress in the understanding of the tumour-immunity cycle, which controls the delicate balance between the immune system and tumour. Identification of cancer cell T-cell inhibitory signals, including PD-L1, has generated novel insight into how to reinvigorate the patients’ immune cells to respond to a variety of tumour types. PD-1 and PD-L1 (PD) inhibitory pathway blockade appears to a highly promising therapy and could accomplish durable anti-tumour responses with a reasonable toxicity profile. Some of the FDA-approved mAbs can reverse the negative regulators from tumour cells and antigen presenting cells of T-cell function to treat some cancer types by blocking the PD signalling pathway,especially advanced solid tumours. Emerging clinical data suggest that cancer immunotherapy will become a significant part of the clinical treatment of cancer.
Statistics from Altmetric.com
XW and SH contributed equally,
LZ and XW contributed equally.
Contributors XW, SH and YZ wrote the manuscript, LZ and XLW reviewed and edited the final manuscript.
Funding Xiaoliang Wu was supported by Guizhou Provincial People’s Hospital Youth Funding (No.GZSQN 20), and Lin Zhu was supported by Guizhou Province Science and Technology Cooperation Funding (No. QKH.LH7482) and Youth Technology Talent Growth Project of Guizhou Province Education Bureau (No.KY206).
Competing interests None declared.
Provenance and peer review Not commissioned; externally peer reviewed.
Data sharing statement Authors agree to share all data. Please contact the corresponding authors.
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.